Novel treatment modalities for cardiovascular prevention are emerging rapidly. Since it is virtually impossible to evaluate all these new compounds in long-term trials using clinical end points, there is an urgent need for validated surrogate markers of atherosclerosis to save both time and costs. Over the last decade, the use of imaging markers has been widely introduced into drug-development strategies. Here we will discuss the most commonly used techniques.
Introduction
Atherosclerosis is an inflammatory process that causes lesions in both large and medium-sized arteries. The disease progresses slowly over many decades, causing clinical manifestations only at advanced stages of the atherosclerotic process. Due to this protracted time course, cardiovascular prevention trials using clinical end points usually require long-term follow up and a large number of participants in order to be able to demonstrate clinical benefit of pharmaceutical interventions [1] . The corresponding studies are both expensive and time consuming [2] . One of the consequences is that innovative drugs may be withheld from patients for many years, awaiting final proof of efficacy [3] . To circumvent these issues, surrogate markers are increasingly being used in cardiovascular intervention studies [2] . This review addresses the available imaging modalities of both the arterial wall and the arterial lumen, which are currently being used as surrogate markers.
Non-invasive and invasive imaging of atherosclerosis
Techniques for imaging atherosclerosis have undergone radical improvements in recent years. An overview of the current arsenal of non-invasive and invasive imaging techniques is presented here.
Flow-mediated dilatation
The crucial role of the vascular endothelium as a first-line defense mechanism against atherogenic insults has been generally acknowledged. All known cardiovascular risk factors, such as hypertension [4] , smoking [5] , hypercholesterolemia and diabetes mellitus [6] have been shown to contribute to onset of endothelial dysfunction. In line with this, endothelial dysfunction is one of the earliest stages of atherogenesis, preceding the occurrence of atherosclerotic lesion formation [7] . More recently, endothelial dysfunction has also been shown to have predictive value for cardiovascular events [8, 9] . Besides invasive techniques to measure endothelial function using intra-arterial infusion of selective endothelial agonists, the introduction of flow-mediated dilatation (FMD) to test endothelial function has paved the way for wider application [10, 11] . The basic principle of this measurement pertains to the induction of increased blood flow in the brachial artery, following deflation of an occluding forearm cuff. The ensuing reactive hyperemia causes increased shear stress at the level of the endothelium of the brachial artery, which induces production of nitric oxide, resulting in relaxation of vascular smooth muscle cells [12] . The ensuing diameter increase of the brachial artery can be measured using ultrasound diameter measurements. The advantages of this technique are its non-invasive and readily applicable nature. However, substantial variation in reproducibility has been described, due to both differences in technical protocols and the impact of physiological factors on FMD [10] . Careful standardization of the protocol, including the implementation of automated real-time vessel-boundary detection, has contributed significantly to reducing the variability (Fig. 1 ). Yet, FMD values in healthy middleaged subjects may still vary extensively, ranging from 5 to 21% [13] . The large interindividual variation limits the use of FMD as an individual cardiovascular risk marker. In spite of these shortcomings, FMD has proven to be a valuable parameter to evaluate changes in endothelial function at a group level [14] .
B-mode ultrasound carotid intima-media thickness
High-resolution B-mode ultrasonography of the carotid arterial far-wall enables visualization of the distance between the lumen-intima interface and mediaadventitia interface, reflecting the carotid intima-media thickness (CIMT; Fig. 2 ). This non-invasive technique allows for real-time in vivo imaging of all stages of atherosclerosis, going from the normal arterial wall to complete arterial occlusion.
Accordingly, arterial wall thickness can be measured as a continuous variable from childhood to old age, in patients as well as in healthy controls [15] . The great variability in measurement protocols that could affect clinical-trial outcomes obviates the need for standardization of these protocols to permit reliable comparison of study results.
Nevertheless, under standardized conditions, the technique of CIMT offers good reproducibility. This makes it suitable for application in relatively small, comparative studies investigating vascular pathophysiology, as well as in large, multicenter clinical trials.
Three large, observational studies utilizing intima-media thickness (IMT) as a surrogate marker for cardiovascular disease are the Atherosclerosis Risk in Communities study [16] , the Cardiovascular Health study [17] and the Rotterdam study [18, 19] . In the Atherosclerosis Risk in Communities study (n ¼ 12 841), it was possible to use IMT to assess all stages of atherosclerosis and IMT proved an independent predictor of coronary artery disease. These findings were confirmed in the subsequent Cardiovascular Health study (n ¼ 5858) and the Rotterdam study (n ¼ 8000).
In addition, statin-intervention trials such as ASAP [20] , REGRESS [21, 22] and ARBITER-I [23] , have underscored the value of CIMT as an efficient parameter to assess efficacy of lipid treatment. Both ASAP and ARBITER-I showed that aggressive lipid lowering with 80 mg of atorvastatin was associated with a decrease in CIMT as opposed to no change or progression in the comparative low-dose-statin arms.
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Figure 1. Flow-mediated dilatation
Image frame of automated measurements of the brachial arterial lumen and the associated flow-mediated dilatation curve (Brachial Analyzer; MIA Vascular Tools, Coralville, IA, USA). y-axis: brachial lumen diameter (mm); x-axis: image frame numbers (obtained every third heart beat). Brachial flow-mediated dilatation in this example is (4.62-4.34)/ 4.34 Â 100 ¼ 6.5%.
Figure 2. B-mode intima-media thickness
High-resolution 15 MHz B-mode ultrasound image of the distal common carotid artery far-wall in a healthy 23-year-old volunteer. The vertical arrow indicates the carotid dilatation, just proximal of the carotid bulb. Intima-media thickness is defined as the distance between the lumen-intima and the media-adventitia interfaces (upper and lower red lines respectively). Measurements are done along a 10-mm length of the wall. The average (AESD) intima-media thickness of this particular wall was 0.049 AE 0.008 mm. Various studies have shown a strong correlation between IMT and cardiovascular risk factors such as low-density lipoprotein cholesterol [24,25 ,26,27 ] , high-density lipoprotein cholesterol [28, 29 ] and blood pressure [30] .
Collectively, carotid IMT has proven to be a wellstandardized and validated surrogate marker for cardiovascular disease and is particularly closely correlated with coronary artery disease (CAD) and the incidence of cardiovascular events such as myocardial infarction and stroke [17, 18, [31] [32] [33] .
Quantitative coronary angiography
In patients with coronary atherosclerosis, angiographically determined progression of the disease is one of the major factors determining clinical prognosis [34, 35, 36 ] . This makes serial angiography a 'validated' technique as a surrogate marker for cardiovascular risk, Three-dimensional reconstruction of cardiovascular magnetic resonance of a carotid artery for a normal subject (left) and a patient with carotid artery atherosclerosis (right). The inner and outer borders of the carotid artery have been analysed semi-automatically with specialized software (Atheroma-Tools, www.CMRtools.com) and the total wall volume has been calculated from the difference. This is a sensitive measure of atherosclerosis burden that is highly reproducible, allowing longitudinal changes in atheroma to be followed, especially with drug interventions, in small sample sizes. The total wall volume for the normal subject (left) is considerably lower than that of the patient with carotid atherosclerosis (right) and the arrows indicate a particular area of wall thickening at the carotid bulb. which has been used successfully in many multicenter trials [21, 36 ] . Coronary atherosclerosis is a complex process that is not limited to focal areas of the coronary artery tree [37] . Therefore, to assess the effect of an intervention on progression or regression of coronary atherosclerosis, both focal (minimal lumen/obstruction diameter) and diffuse (mean lumen diameter) changes should be measured [36 ] . Visual interpretation of coronary angiograms has its limitations because (i) assessment of stenosis severity is associated with a large intraand inter-observer grading variability (8-37%), (ii) only relative stenosis measurements are provided and (iii) the severity of diffuse atherosclerosis is difficult to estimate. Therefore, quantitative coronary angiography (QCA), providing absolute diameters in millimeters, is now the established standard [38] (Fig. 3 ). Of note, early stages of coronary atherosclerosis are associated with remodeling of the coronary artery [39] , resulting in preservation of the lumen cross-sectional area. Consequently, early-stage coronary atherosclerosis is angiographically undetectable [40] . This often causes underestimation of the severity and extent of coronary atherosclerosis when compared to postmortem pathological studies [41] . Despite the limitations, standardized QCA has proven itself as a worthwhile technique, carrying important prognostic information.
Computed-tomography coronary imaging
Non-invasive visualization of the coronary arteries puts any diagnostic technique to the test, because the coronaries are small and tortuous, and respiratory motion and the continuous cardiac motion distorts the image. Thus, high temporal resolution is required to 'freeze' the heart to produce a sharp image. Despite these hurdles computed-tomography scanners are able to visualize the coronary arteries.
Electron-beam computed tomography
Electron-beam computed tomography (EBCT) can accurately and reproducibly quantify the presence of coronary calcium in the coronary tree. Whereas the coronary calcification score correlates well with total atherosclerotic plaque burden, it only reflects the presence of advanced lesions. Several studies have shown that coronary artery calcium is a marker of increased risk for adverse coronary events [42] , independently from other CV risk factors [43 ,44] . To date, only few studies are available, reporting decreased progression of coronary artery calcium during active treatment [45] .
Multidetector computed tomography
Multidetector computed-tomography coronary imaging represents cross-sectional imaging of the coronary lumen and wall, which allows quantification of coronary plaques as well as the artery wall [46 ,47 ] . In addition, valuable information with respect to the composition of the plaque can be obtained based on the differences of the computed-tomography density values [48 ,49] (Fig. 4) . Based on the presence or distribution of plaques (one-, two-or three-vessel disease) and stenosis severity (>50% diameter stenosis) one can establish the plaque burden of the coronary tree [50 ] . However, it remains to be established whether the computed-tomography assessment of the coronary plaque burden is accurate in stratifying cardiac risk. In addition, further studies are needed to further explore the ability of multidetector computed tomography to assess disease progression, stabilization or even regression following specific therapy.
Cardiovascular magnetic resonance
Cardiovascular magnetic resonance (CMR) is a relatively new technique in the assessment of atherosclerosis. New sequences allow the vessel wall to be imaged such that either its area (two-dimensional technique) or volume (three-dimensional technique) can be measured and followed over time (Fig. 5 ). The three-dimensional technique has the merit of being less dependent on slice positioning in longitudinal studies, and is a more sensitive test, because the area of many slices is added to generate a vessel-wall volume [51] . Most work has been performed in the carotid artery because its closeness to the surface allows it to be imaged in high resolution. The threedimensional technique samples about 3 cm either side of the carotid bifurcation and has an interstudy reproducibility of 4.4% [52 ] . The vessel-wall volume is the difference between the external wall volume and the luminal volume, and semi-automated software is now available to make these measurements reliably and quickly (Atheroma-Tools; CVIS, London, UK).
A number of studies in humans have assessed CMR in the longitudinal measurement of atheroma. Mohiaddin et al.
[53 ] showed atheroma progression in untreated aortic plaque area over 2 years. Corti et al. [54 , 55 ] showed that simvastatin caused regression of aortic and carotid artery atheromaareaover12[54 ]and24 months [55 ] .Limaet al. [56 ] showed that simvastatin could induce regression of aortic plaque volume after only 6 months of treatment. Yonemura et al. [57 ] showed regression of aortic plaque area after 12 months of simvastatin treatment. In conclusion, atheroma CMR is beginning to be used for longitudinal follow up of patients to investigate atheroma progression and regression. The good reproducibility has allowed current trials to be conducted in small samples sizes (approx. 40 patients) over reasonable time periods (12 months) to show statistically significant effects.
Intravascular ultrasound
Intravascular ultrasound is performed during cardiac catheterization using small, intracoronary catheters. The strong ultrasound signal reflected from the intima and external elastic membrane (EEM) allows real-time intraluminal imaging of the vessel wall and measurement of the atheroma (intima-media area) [58, 59] . Initial quantitative intravascular-ultrasound studies examined the progression of plaque area at diseased lesion sites [60] . However, the reproducibility of this analysis approach was limited by the difficulties to exactly match individual sites. Accordingly volumetric-analysis approaches integrate consecutive plaque-area measurements at 0.5-1 mm intervals along long vessel segments (Fig. 6 ). Because the segment rather than individual sites are matched at baseline and follow up, assessment of small percentage changes in atheroma volume is possible with considerable statistical power [61,62,63 ,64 ,65,66 ] . In a recent randomized trial, intra-observer variability was analyzed in 1177 images from 18 patients [64 ]. The mean (AESD) differences were negligible for both EEM (À0.16 AE 0.68 mm 2 ) and lumen areas (À0.02 AE 0.75 mm 2 ). Linear regression analysis showed close correlations between the original and re-analysis (r ¼ 0.99 and 0.98 for EEM and lumen areas). Interobserver variability was evaluated in 2151 images from 30 patients. The mean (SD) differences were negligible for both EEM (À0.07 AE 0.93 mm 2 ) and lumen areas (À0.07 AE 0.93 mm 2 ). Regression analysis showed close correlations between the original and re-analysis (r ¼ 0.99 and 0.98 for EEM and lumen areas).
Results from randomized, serial intravascular-ultrasound studies collectively demonstrate either arrest of progression or actual regression during intensive lipidmodifying therapies [61,62,63 ,64 ,65,66 ] . Sub-studies have also demonstrated the independent role of the inflammatory marker C-reactive protein [67 ] . The comparison of these intravascular-ultrasound trials with outcome studies using similar pharmacological interventions provide indirect data correlating plaque burden to clinical outcomes [64 , 67 ,68 ,69 ] . Collectively, these studies underscore the validity of volumetric plaque burden as an end point for the assessment of atherosclerosis progression/regression.
Conclusion
At present, the use of IMT as a surrogate marker has several advantages compared to other imaging techniques: it is easy to use, non-invasive, has a good reproducibility and has the capacity to identify atherosclerosis progression and regression. At the same time, the validity of the method is supported by a large number of clinical trials. Whereas FMD also has predictive value for future cardiovascular disease, this method is of limited use due to large inter-individual variation. Coronary angiography has traditionally been the gold-standard imaging modality to assess coronary atherosclerosis progression and regression. However, this technique identifies only the arterial lumen and fails to identify early stages of the disease. EBCT reliably quantifies calcium content in the coronary arteries. However, EBCT solely identifies advanced plaques. CMR has evolved rapidly as a means to assess carotid and coronary plaque area and volume. Further data are awaited to evaluate its reliability as a surrogate marker for CAD. Intravascular ultrasound permits assessment of plaque burden in vivo. Whereas changes in plaque burden as measured by intravascular ultrasound may well be the most direct way to evaluate the effect of an anti-atherosclerotic agent, its predictive value for future CV events remains to be established.
In summary, ultrasound IMT of the carotid arteries is considered the predominant non-invasive surrogate marker for cardiovascular disease, albeit in a non-coronary vessel, whereas intravascular ultrasound is the preferred tool for invasive assessment of atherosclerotic disease where it is most relevant: in the coronary arteries. 
